Talquetamab

What it is used for

TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Side effects, and when to stop

The following adverse reactions are also described elsewhere in the labeling:

• Cytokine Release Syndrome
• Neurologic Toxicity, including ICANS
• Oral Toxicity and Weight Loss
• Infections
• Cytopenias
• Skin Toxicity
• Hepatotoxicity

Who should not take it

None.

Other medicines and interactions

For certain cytochrome P450 (CYP) substrates, minimal changes in the substrate concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with TALVEY.

Talquetamab-tgvs causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur from initiation of the TALVEY step-up dosing schedule up to 14 days after the first treatment dose and during and after CRS.

Storing it

Store refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light.

Do not freeze.